Recent Research Analysts’ Ratings Updates for Billiontoone (BLLN)

Billiontoone (NASDAQ: BLLN) has recently received a number of price target changes and ratings updates:

• 3/7/2026 – Billiontoone was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/5/2026 – Billiontoone had its price target lowered by Wells Fargo & Company from $110.00 to $90.00. They now have an “equal weight” rating on the stock.
• 3/5/2026 – Billiontoone had its “buy” rating reaffirmed by Guggenheim. They now have a $120.00 price target on the stock.
• 3/5/2026 – Billiontoone had its price target lowered by BTIG Research from $160.00 to $140.00. They now have a “buy” rating on the stock.
• 2/3/2026 – Billiontoone is now covered by Weiss Ratings. They set a “sell (d)” rating on the stock.

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.